# Mirtazapine

## Apa-Mirtazapine O.D.T. 30mg

| TAH Drug Code      | [OMIRT3](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OMIRT3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|:-------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Major depressive disorder.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Dosing             | Adults: Initial dose is 15 or 30 mg/day (higher dose at night). Effective dose typically ranges from 15-45 mg. Treatment should continue for 4-6 months until symptoms fully resolve, then gradually taper off. Symptoms usually improve within 2-4 weeks; if not, increase to maximum dose. If no improvement after an additional 2-4 weeks, discontinue treatment.                                                                                                                                                                                                                                                                                                                                                      |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Contraindications  | Hypersensitivity to mirtazapine or any component of the formulation. Use of monoamine oxidase inhibitors (MAOIs), including IV methylene blue (concurrently or within 14 days of stopping an MAOI).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Adverse Effects    | Common: Constipation (13%), Xerostomia (25%), Asthenia (8%), Dizziness (7%), Disturbance in thinking (3%). Serious: Prolonged QT interval, Torsades de pointes, Ventricular tachycardia, Hyponatremia (<0.1%), Serum cholesterol above reference range (15%), Serum triglycerides above reference range (6%), Weight gain (12%), Increased appetite (17%), Agranulocytosis (0.1%), Neutropenia, ALT/SGPT level raised (Up to 2%), Aspartate aminotransferase serum level above reference range (<1%), Cirrhosis of liver (<0.1%), Liver function tests outside reference range (0.1-1%), Seizure, Somnolence (54%), Angle-closure glaucoma (0.1-1%), Mania (0.2%), Suicidal thoughts, Suicide, Serotonin syndrome (<0.1%) |
| Pregnancy          | No (Limited) Human Data â€“ Animal Data Suggest Moderate Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| More Info          | [UpToDate](https://www.uptodate.com/contents/mirtazapine-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

